Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH6YVD)

• Drug Name: ISC-4 Drug Info
• Synonyms: ISC-6; Isoselenocyanate Akt3 inhibitors (cancer); Isoselenocyanate Akt3 inhibitors (cancer), Penn State Hershey Medical Center

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 25015746
  TTD Drug ID: DMH6YVD

Molecule-Related Drug Atlas

Drug(s) Targeting RAC-gamma serine/threonine-protein kinase (AKT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[2]
ARQ 092	DM5WK0J	Proteus syndrome	LD2C	Phase 2	[3]
MK-2206	DMT1OZ6	Rectal adenocarcinoma	2B92	Phase 2	[4]
GSK2141795	DMSHE70	Colorectal cancer	2B91.Z	Phase 2	[5]
M2698	DM3PVBJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
LYS-6KAKT1	DMLXGAI	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
LY2780301	DM93AJW	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
XL418	DME0F5W	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
SR13668	DMO5760	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
TCN-P	DMV0AH8	Acute myeloid leukaemia	2A60	Phase 1	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
RAC-gamma serine/threonine-protein kinase (AKT3)	TTAZ05C	AKT3_HUMAN	Inhibitor	[1]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2286).
• [2] The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5.
• [3] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [4] First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.J Clin Oncol.2011 Dec 10;29(35):4688-95.
• [5] Inhibiting the akt pathway in cancer treatment: three leading candidates. P T. 2011 Apr;36(4):225-7.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] DOI: 10.1016/S1359-6349(10)71767-5
• [8] A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 2015 Jun;33(3):710-9.
• [9] Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer
• [10] Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prev Res (Phila). 2011 Mar;4(3):347-53.
• [11] Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.Invest New Drugs.2011 Dec;29(6):1381-9.